Usage of Dapagliflozin - a Sodium Glucose Co-transporter Inhibitor, in the managEment of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms FOREFRONT
- Sponsors AstraZeneca
- 22 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2017 Status changed from not yet recruiting to recruiting.
- 09 Mar 2017 New trial record